DS
PRME icon

David Shaw’s Prime Medicine PRME Stock Holding History

David Shaw’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Sell
648,940
-744,681
-53% -$2.47M ﹤0.01% 3051
2026
Q1 		$4.85M Sell
1,393,621
-157,748
-10% -$600K ﹤0.01% 2201
2025
Q4 		$5.38M Sell
1,551,369
-664,483
-30% -$2.96M ﹤0.01% 2239
2025
Q3 		$12.3M Buy
+2,215,852
New +$9M 0.01% 1525
2024
Q4 		– Sell
-139,451
Closed -$540K – 4771
2024
Q3 		$540K Buy
139,451
+94,016
+207% +$436K ﹤0.01% 3653
2024
Q2 		$234K Buy
45,435
+18,767
+70% +$114K ﹤0.01% 4015
2024
Q1 		$187K Buy
+26,668
New +$202K ﹤0.01% 3935

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

David Shaw's PRME Position: Q2 2026 in Review

David Shaw reduced its Prime Medicine (PRME) stake by 53% in Q2 2026, selling an estimated $2.47M and leaving 648,940 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3051.

David Shaw first reported a position in PRME in Q1 2024 and has held it in 7 quarters since. The position peaked at $12.3M in Q3 2025. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • David Shaw held 648,940 shares of Prime Medicine worth $2.39M as of Q2 2026.
  • David Shaw sold 744,681 Prime Medicine shares in Q2 2026, an estimated $2.47M.
  • Prime Medicine made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3051 holding.
  • David Shaw first reported a position in Prime Medicine in Q1 2024 and has held it in 7 quarters since.
  • David Shaw's Prime Medicine position peaked at $12.3M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.